tradmap

GLMD Financials Galmed Pharmaceuticals Ltd.

10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Revenue & net income
-$32M -$15M $2M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
-1140% -570% 0% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$33M -$16M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $12M $24M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$60M $10M $80M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$10M $4M
2024 -$8M $5M
2023 -$7M $3M
2022 -$18M -$19M $2M
2021 -$32M -$33M $3M
2020 $0 -$29M -$26M $7M
2019 $0 -$20M -$15M $16M
2018 $2M 0.0% -525.8% -$9M $24M
2017 $1M 0.0% -1139.5% -$12M $0 $13M
2016 $467000 0.0% 0.0% -$12M $796000 $3M

Frequently asked questions

Is GLMD growing its revenue and profit?

See the revenue and net-income charts above for Galmed Pharmaceuticals Ltd.'s multi-year trend.

How much debt does GLMD have?

As of FY2025, Galmed Pharmaceuticals Ltd. reported — of total debt against $4M of cash.

What is GLMD's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.